Omeros (OMER) Cash from Financing Activities (2010 - 2026)
Omeros (OMER) posted Cash from Financing Activities of -$22.0 million for Q1 2026, up 65.89% sequentially from -$64.4 million in Q4 2025, and down 1095.32% YoY from $2.2 million in Q1 2025.
Analysis
Omeros (OMER) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Omeros has reported Cash from Financing Activities for 17 years, with the latest figure at -$22.0 million in Q1 2026.
- Quarterly Cash from Financing Activities fell 1095.32% year-over-year to -$22.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$62.3 million (down 66.66% YoY) and the FY2025 annual result came in at -$42.2 million, down 167.06% from the prior year.
- Cash from Financing Activities advanced to -$22.0 million in Q1 2026 per OMER's latest filing, from -$64.4 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $124.8 million in Q3 2022 and troughed at -$105.0 million in Q4 2023.
- A 5-year average of $993764.7 and a median of -$651000.0 in 2022 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities soared 26016.53% in 2022, then slumped 16021.81% in 2023.
- Over 5 years, Cash from Financing Activities stood at -$651000.0 in 2022, then plunged by 16021.81% to -$105.0 million in 2023, then soared by 96.1% to -$4.1 million in 2024, then tumbled by 1473.6% to -$64.4 million in 2025, then soared by 65.89% to -$22.0 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$22.0 million, -$64.4 million, and $25.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Omeros | 1.38 Bn | 1.38 Bn | 27.73 Mn | -7.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7.47 Mn |
| Mar 31, 2026 | -21.98 Mn |
| Dec 31, 2025 | -64.44 Mn |
| Sep 30, 2025 | 25.83 Mn |
| Jun 30, 2025 | -1.72 Mn |
| Mar 31, 2025 | -1.84 Mn |
| Dec 31, 2024 | -4.10 Mn |
| Sep 30, 2024 | -4.58 Mn |
| Jun 30, 2024 | -26.88 Mn |
| Mar 31, 2024 | 98.43 Mn |
| Dec 31, 2023 | -104.95 Mn |
| Sep 30, 2023 | -483,000.00 |
| Jun 30, 2023 | -260,000.00 |
| Mar 31, 2023 | -388,000.00 |
| Dec 31, 2022 | -651,000.00 |
| Sep 30, 2022 | 124.84 Mn |
| Jun 30, 2022 | -99,000.00 |
| Mar 31, 2022 | 161,000.00 |
| Dec 31, 2021 | -810,000.00 |
| Sep 30, 2021 | 478,000.00 |